Company Overview of Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.
6400 Westwind Way
Crestwood, KY 40014
Founded in 2009
Key Executives for Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. Key Developments
Similar Private Companies By Industry
|Celvive, Inc.||United States|
|Mpex Pharmaceuticals, Inc.||United States|
|Transplant Technologies of Texas, Ltd.||United States|
|Jade Therapeutics, Inc.||United States|
|Celgene Avilomics Research, Inc.||United States|
Recent Private Companies Transactions
December 5, 2014
December 2, 2014
To contact Apellis Pharmaceuticals, Inc., please visit www.apellis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.